Centre for Infectious Diseases and Epidemiology, University of Cape Town, Cape Town, South Africa.
Epicentre, Cape Town, South Africa.
PLoS One. 2018 Nov 26;13(11):e0207656. doi: 10.1371/journal.pone.0207656. eCollection 2018.
Latest WHO guidelines recommend starting HIV-positive individuals on antiretroviral therapy treatment (ART) regardless of CD4 count. We assessed additional impact of adopting new WHO guidelines.
We used data of individuals aged 15-59 years from three HIV population surveys conducted in 2012 (Kenya) and 2013 (Malawi and South Africa). Individuals were interviewed at home followed by rapid HIV and CD4 testing if tested HIV-positive. HIV-positive individuals were classified as "eligible for ART" if (i) had ever been initiated on ART or (ii) were not yet on ART but met the criteria for starting ART based on country's guidelines at the time of the survey (Kenya-CD4< = 350 cells/μl and WHO Stage 3 or 4 disease, Malawi as for Kenya plus lifelong ART for all pregnant and breastfeeding women, South Africa as for Kenya plus ART for pregnant and breastfeeding women until cessation of breastfeeding).
Of 18,991 individuals who tested, 4,113 (21.7%) were HIV-positive. Using country's ART eligibility guidelines at the time of the survey, the proportion of HIV-infected individuals eligible for ART was 60.0% (95% CI: 57.2-62.7) (Kenya), 73.4% (70.8-75.8) (South Africa) and 80.1% (77.3-82.6) (Malawi). Applying WHO 2013 guidelines (eligibility at CD4< = 500 and Option B+ for pregnant and breastfeeding women), the proportions eligible were 82.0% (79.8-84.1) (Kenya), 83.7% (81.5-85.6) (South Africa) and 87.6% (85.0-89.8) (Malawi). Adopting "test and treat" would mean a further 18.0% HIV-positive individuals (Kenya), 16.3% (South Africa) and 12.4% (Malawi) would become eligible. In all countries, about 20% of adolescents (aged 15-19 years), became eligible for ART moving from WHO 2013 to "test and treat" while no differences by sex were observed.
Countries that have already implemented 2013 WHO recommendations, the burden of implementing "test and treat" would be small. Youth friendly programmes to help adolescents access and adhere to treatment will be needed.
最新的世界卫生组织(WHO)指南建议无论 CD4 计数如何,都应开始对 HIV 阳性个体进行抗逆转录病毒治疗(ART)。我们评估了采用新的 WHO 指南的额外影响。
我们使用了 2012 年(肯尼亚)和 2013 年(马拉维、南非)三次 HIV 人群调查中 15-59 岁个体的数据。个体在家中接受访谈,然后对 HIV 阳性个体进行快速 HIV 和 CD4 检测。如果 HIV 阳性个体曾经接受过 ART 治疗或尚未接受 ART 治疗,但根据调查时该国指南(肯尼亚为 CD4< = 350 个/μl 和 WHO 第 3 或 4 期疾病,马拉维为所有妊娠和哺乳期妇女终身接受 ART,南非为妊娠和哺乳期妇女接受 ART,直至停止母乳喂养)符合开始 ART 的标准,则将其归类为“符合 ART 治疗条件”。
在接受检测的 18991 人中,有 4113 人(21.7%)HIV 阳性。使用调查时国家的 ART 资格标准,符合 ART 治疗条件的 HIV 感染者比例为 60.0%(95%CI:57.2-62.7)(肯尼亚)、73.4%(70.8-75.8)(南非)和 80.1%(77.3-82.6)(马拉维)。应用 WHO 2013 年指南(CD4< = 500 时符合资格,妊娠和哺乳期妇女采用 Option B+),符合条件的比例分别为 82.0%(79.8-84.1)(肯尼亚)、83.7%(81.5-85.6)(南非)和 87.6%(85.0-89.8)(马拉维)。采用“检测即治疗”,肯尼亚、南非和马拉维分别会有 18.0%、16.3%和 12.4%的 HIV 阳性个体符合治疗条件。在所有国家,约 20%的青少年(15-19 岁)从符合 WHO 2013 年指南到“检测即治疗”后,符合接受 ART 治疗的条件,而性别之间没有差异。
对于已经实施 2013 年 WHO 建议的国家,实施“检测即治疗”的负担将很小。需要制定对青少年友好的方案,以帮助他们获得并坚持治疗。